Tenapanor: all 36 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsRecruitingNCT07382167Phase 3
• Tenapanor in Synucleinopathy-Related ConstipationRecruitingNCT06460038Phase 2
• Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CEnrolling by invitationNCT05905926Phase 3
• A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk.CompletedNCT06481150Phase 4Results posted
• Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaCompletedNCT04549597Phase 4Results posted
• A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HPCompletedNCT03988920Phase 4Results posted
• Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyCompletedNCT03824587Phase 2/3Results posted
• A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisCompletedNCT03427125Phase 3Results posted
• A Long-Term Safety Study of Tenapanor for the Treatment of IBS-CCompletedNCT02727751Phase 3Results posted
• A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-CCompletedNCT02686138Phase 3Results posted
• An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)CompletedNCT02675998Phase 3Results posted
• A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-CCompletedNCT02621892Phase 3Results posted
• Dose Finding Study to Treat High Phosphate Levels in the Blood.CompletedNCT02081534Phase 2Results posted
• The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)CompletedNCT01923428Phase 2/3Results posted
• A Study in CKD Patients With Type 2 Diabetes Mellitus and AlbuminuriaCompletedNCT01847092Phase 2Results posted
• Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on HemodialysisCompletedNCT01764854Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)CompletedNCT01340053Phase 2Results posted
• Assessing Tenapanor as a Treatment of CF-related Constipation.Active, not recruitingNCT06810167Phase 3
• 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsCompletedNCT06553547Phase 2
• An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating FemalesCompletedNCT06203444Phase 1
• Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With ConstipationCompletedNCT05995899Phase 4
• Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsCompletedNCT05643534Phase 3
• Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisCompletedNCT04771780Phase 3
• Clinical Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisCompletedNCT04767581Phase 3
• Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on HemodialysisCompletedNCT04766398Phase 3
• Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal DialysisCompletedNCT04766385Phase 3
• Dose-finding Study of KHK7791 in Hyperphosphatemia PatientsCompletedNCT03864458Phase 2
• Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia PatientsCompletedNCT03864445Phase 2
• A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HDCompletedNCT03831607Phase 2
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy VolunteersCompletedNCT02819687Phase 1
• Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy VolunteersCompletedNCT02796131Phase 1
• A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 FormulationsCompletedNCT02249936Phase 1
• D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy SubjectsCompletedNCT02226783Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese SubjectsCompletedNCT02176252Phase 1
• To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy VolunteersCompletedNCT02140268Phase 1
• AZD1722 Open Label, Absorption Distribution Metabolism and Excretion StudyCompletedNCT02063386Phase 1

← Tenapanor overview